Alsadoun Lara, Ul Hassan Hasnat, Kalansuriya Imesha, Bai Riya, Raut Yogesh, Jameel Hind, Rehman Abdur, Kadri Faizan, Anika Nabila N, Khattak Abid Umar, Shehryar Abdullah, Eltayeb Mohamed, Khan Moosa
Trauma and Orthopedics, Chelsea and Westminster Hospital, London, GBR.
Internal Medicine, Niazi Medical and Dental College, Sargodha, PAK.
Cureus. 2024 Sep 1;16(9):e68358. doi: 10.7759/cureus.68358. eCollection 2024 Sep.
This systematic review synthesizes findings from various studies that examine genetic markers associated with susceptibility to gastric cancer. By conducting a comprehensive search across multiple databases, we analyzed studies on the relationship between specific genetic polymorphisms and the risk of developing gastric cancer. Our review highlights significant genetic markers, including mucin 1 (MUC1), prostate stem cell antigen (PSCA), tumor necrosis factor-alpha (TNF-α), DNA methyltransferases (DNMTs), matrix metalloproteinase-7 (MMP-7), and interleukin-8 (IL-8), emphasizing their roles across different ethnic and demographic contexts. The findings demonstrate a robust association between these markers and gastric cancer susceptibility, particularly noting variations in risk among diverse populations. Such variations could inform personalized treatment and screening strategies. The review also underscores the need for further research to explore how these polymorphisms influence cancer development and to confirm their potential clinical applications. We discuss the implications of these genetic markers for global health strategies and personalized medicine, highlighting the importance of integrating genetic testing into current gastric cancer management protocols.
本系统评价综合了各项研究的结果,这些研究探讨了与胃癌易感性相关的基因标记。通过对多个数据库进行全面检索,我们分析了关于特定基因多态性与患胃癌风险之间关系的研究。我们的评价突出了重要的基因标记,包括粘蛋白1(MUC1)、前列腺干细胞抗原(PSCA)、肿瘤坏死因子-α(TNF-α)、DNA甲基转移酶(DNMTs)、基质金属蛋白酶-7(MMP-7)和白细胞介素-8(IL-8),强调了它们在不同种族和人口背景中的作用。研究结果表明这些标记与胃癌易感性之间存在密切关联,尤其指出了不同人群在风险上的差异。这种差异可为个性化治疗和筛查策略提供依据。该评价还强调需要进一步研究,以探索这些多态性如何影响癌症发展,并确认它们的潜在临床应用。我们讨论了这些基因标记对全球健康策略和个性化医学的影响,强调了将基因检测纳入当前胃癌管理方案的重要性。